AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: immunotherapy

newssourceFORcompanyinformationcontent1releasesmarket

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Albany ENT & Allergy Services’ CT Manager Elected President of National Accreditation Body

ALBANY, N.Y., June 26, 2025 /PRNewswire/ -- Albany ENT & Allergy Services (AENT), the Capital Region's leading private otolaryngology practice, proudly congratulates Diane Deyoe, RT,...

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /CNW/ -- Equity Insider News Commentary – Rising rates of cancer...

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmunotherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers